Clinical Manifestations of Protein S Deficiency
Protein S deficiency primarily manifests as recurrent venous thromboembolism (VTE), most commonly presenting as deep vein thrombosis (74%), superficial thrombophlebitis (72%), and pulmonary embolism (38%), with a mean age of first thrombotic event at 28 years 1.
Primary Thrombotic Manifestations
The hallmark presentation involves venous thrombosis that is:
- Recurrent in 77% of symptomatic patients 1
- Unprovoked in 56% of cases (occurring without precipitating factors like surgery, trauma, or immobilization) 1
- Early onset, with only 32% probability of remaining thrombosis-free by age 35 1
Common Sites of Thrombosis
The typical thrombotic events occur in combinations, either simultaneously or in succession:
- Lower extremity deep vein thrombosis - most frequent presentation
- Superficial thrombophlebitis - often accompanies DVT
- Pulmonary embolism - occurs in approximately one-third of patients 1
Unusual Thrombotic Sites
Protein S deficiency can cause thrombosis at atypical locations 2, 1:
- Mesenteric veins - can present with acute abdominal pain, peritoneal signs, and intestinal perforation requiring surgical intervention 2
- Portal veins
- Cerebral veins - presenting as stroke or cerebral infarction 3
- Axillary veins 1
Severe Manifestations (Homozygous/Compound Heterozygous)
In rare cases of severe protein S deficiency (homozygous mutations), life-threatening presentations occur:
- Purpura fulminans at birth 4
- Neonatal thrombosis with massive pulmonary embolism in the first week of life 4
- Recurrent warfarin-induced skin necrosis - paradoxical complication when international normalized ratio drops below 4.0 in severe deficiency 4
Pregnancy-Related Complications
Women with protein S deficiency face specific risks:
- Deep vein thrombosis during pregnancy 3
- Increased thrombotic risk in postpartum period - the time of maximal daily VTE risk 5
Important Clinical Pitfalls
Age of onset: While mean age is 28 years, thrombotic events can occur from adolescence (as young as 15 years) through late adulthood (up to 68 years) 1. Young patients (<40 years) presenting with unprovoked VTE warrant thrombophilia screening 6.
Recurrence pattern: The high recurrence rate (77%) distinguishes protein S deficiency from provoked thrombosis and typically necessitates indefinite anticoagulation after unprovoked, life-threatening events 7.
Combined thrombophilias: Patients carrying additional thrombophilic defects (Factor V Leiden, protein C deficiency, prothrombin mutations) have significantly higher VTE recurrence risk 7. In survival analysis, combined thrombophilic defects were the only variable associated with VTE recurrence (p=0.049) 7.
Quality of life impacts: Beyond thrombotic events, 33% of protein S deficient patients require medications affecting the central nervous system (opioids, antidepressants, antiepileptics, antimigraine drugs, antipsychotics), suggesting significant impact on overall well-being 7.
Associated Laboratory Findings
When evaluating symptomatic patients: